Frank Essmann

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Cell Cycle Arrest

Binding Protein

Induced Apoptosis

Top Venues

Cell death & disease

Cell death discovery

Eberhard-Karls-Universität Tübingen Medizinische Fakultät

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Eberhard-Karls-Universität Tübingen Medizinische Fakultät Jul 01 2008 - Sep 30 2018

Germany

Group Leader :: Interfaculty Institute for Biochemistry

Heinrich-Heine-Universität Düsseldorf Medizinische Fakultät Sep 01 2002 - Jun 30 2008

Germany

Junior Group Leader :: Institute for Molecular Medicine

Proteome Factory AG Aug 01 2001 - Aug 31 2002

Germany

Head :: Analysis and Interpretation

Charite Berlin / MDC Berlin Oct 01 1997 - Jul 31 2001

Germany

PhD / PostDoc

Publications

Tobias B Beigl, Alexander Paul, Thomas P Fellmeth, Dang Nguyen, Lynn Barber, Sandra Weller, Benjamin Schäfer, Bernhard F Gillissen, Walter E Aulitzky, Hans-Georg Kopp, Markus Rehm, David William Andrews, Kristyna Pluhackova, Frank Essmann
BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains. EMBO reports (2024)
Sandra Weller, Astrid Toennießen, Benjamin Schaefer, Tobias Beigl, Alina Muenchow, Kathrin Böpple, Ute Hofmann, Bernhard F Gillissen, Walter E Aulitzky, Hans-Georg Kopp, Frank Essmann
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. Cell death discovery 8 (1) (2022)
Stephanie Busche, Katharina John, Franziska Wandrer, Florian W R Vondran, Ulrich Lehmann, Heiner Wedemeyer, Frank Essmann, Heike Bantel, Heike Bantel
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. Cell death & disease 12 (8) (2021)
Alina Muenchow, Sandra Weller, Clemens Hinterleitner, Elke Malenke, Stefanie Bugl, Stefan Wirths, Martin R Müller, Heike Bantel, Walter E Aulitzky, Hans-Georg Kopp, Frank Essmann
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. Cell death & disease 11 (8) (2020)